5AM Ventures — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtech
Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)
Co-investorsARCH Venture PartnersAtlas VentureSanofi Ventures
Latigo Bio is a clinical-stage biopharmaceutical company developing non-opioid pain medicines intended to block pain transmission without addiction risk.
BiotechHealthtechThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)Kevin Raidy(Director)
Board seatDeborah Palestrant· per SEC Form D · $150M raise · filed Feb 2025
Co-investorsAccess BiotechnologyForesite CapitalKern Capital, LLCSanofi VenturesWestlake Village BioPartners
Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD).
BiotechHealthtechBerkeley, US
Jeremy Reiter(Scientific Co-Founder)Markus Delling(Scientific Co-Founder)Thomas Gustafson(Executive Officer)Emily Conley(Executive Officer, Director)
BoardEvan Caplan(Director)inCharlotte McKee(Director)
Co-investorsOrbiMedAtlas VentureQiming Venture Partners USA
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.